Drug Development

First patient enrolled in phase Ib/II trial of ARQ 501, gemcitabine

Published in Cancer Weekly, February 15th, 2005

ArQule, Inc., (ARQL) announced that it has successfully enrolled its first patient in a phase Ib/II combination trial of ARQ 501 and gemcitabine.

The phase 1b component is an open label dose escalation study that is being conducted at two leading clinical research sites within the United States, enrolling patients with advanced cancer, some of whom may have previously received gemcitabine.

ArQule anticipates that this component will be followed by a phase II study exploring the use of ARQ 501 and gemcitabine in patients with advanced cancer. The phase Ib/II study is being conducted by ArQule as part of its strategic alliance with Roche to explore...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-02-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry